A Structured Classification of Pyrotinib-Containing Neoadjuvant Regimens for HER2-Positive Breast Cancer: Efficacy,
Jiani Liu1, Xinyu Peng2, Yang Yang3
1Department of Breast Surgery, Baoding No. 1 Central Hospital, Baoding, Hebei, 071000, People's Republic of China.
Breast Cancer (Dove Medical Press)
|May 27, 2026
Summary
Pyrotinib-based neoadjuvant regimens for HER2-positive breast cancer show varying pathological complete response rates (28-74%) and toxicity. Optimal selection requires matching regimens to tumor characteristics and patient factors.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- HER2-positive breast cancer requires effective neoadjuvant therapy.
- Pyrotinib is an emerging targeted therapy option.
Purpose of the Study:
- To classify pyrotinib-containing neoadjuvant regimens for HER2-positive breast cancer.
- To evaluate pathological complete response (pCR) rates and adverse events.
- To provide a framework for selecting optimal pyrotinib-based regimens.
Main Methods:
- Structured literature review.
- Categorization of regimens into four strategies: chemotherapy, trastuzumab plus chemotherapy, cell-cycle inhibitors, and antibody-drug conjugates (ADCs).
- Summarization of pCR rates and toxicity profiles.
Main Results:
- pCR rates ranged from 28% to 74% across different pyrotinib-based regimens.
- Significant variations in grade ≥3 toxicity patterns were observed.
- Regimen selection should consider tumor characteristics (HR status, HER2 level, subtype) and patient factors (age, cardiac risk).
Conclusions:
- Optimal pyrotinib-based neoadjuvant therapy selection is personalized.
- Further research is needed on biomarker-driven selection, long-term outcomes, and direct comparisons with standard therapies like trastuzumab plus pertuzumab.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...